4.7 Article

Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase

期刊

STROKE
卷 53, 期 10, 页码 3235-3237

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.122.040219

关键词

alteplase; immunogenicity; kinetics; staphylokinase; stroke; thrombolysis

资金

  1. Czech Ministry of Education [INBIO -CZ.02.1, 01/0.0/0.0/16_026/0008451, ENOCH -CZ.02.1.01/0.0/0.0/16_019/0000 868, LX22NPO5107]
  2. Grant Agency of Czech Republic [20-15915Y]

向作者/读者索取更多资源

The burden of strokes is increasing, and current therapeutic drugs are not ideal. Staphylokinase has been identified as a potential thrombolytic agent that is efficient, fibrin-selective, inexpensive, and can evolve. Recent findings have shown that a nonimmunogenic variant of staphylokinase is comparable to alteplase, with a reduced risk of intracranial hemorrhage and the advantage of single bolus administration. Furthermore, detailed analysis has revealed a bottleneck in staphylokinase's activity that, if eliminated, could provide up to 1000-fold higher activity than alteplase. These limitations provide new possibilities for improvement by protein engineers.
Stroke burden is substantially increasing but current therapeutic drugs are still far from ideal. Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective, inexpensive, and evolvable thrombolytic agent. The emphasis is escalated by new recent findings. Staphylokinase nonimmunogenic variant was proven noninferior to alteplase in a clinical trial, with decreased risk of intracranial hemorrhage and the advantage of single bolus administration. Furthermore, our detailed kinetic analysis revealed a new staphylokinase limiting bottleneck whose elimination might provide up to 1000-fold higher activity than the clinically approved alteplase. This knowledge of limitations unlocks new possibilities for improvements that are now achievable by the community of protein engineers who have the required expertise and are ready to transform staphylokinase into a powerful molecule. Collectively, the noninferiority and safety of nonimmunogenic staphylokinase together with the newly identified effectivity limitation make staphylokinase a perfect candidate for further exploration, modification, and advancement to make it the next-generation widely accessible thrombolytic drug effectively treating stroke all around the world, including middle- and low-income countries.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据